• news.cision.com/
  • CLS/
  • Clinical Laserthermia Systems receives SEK 5.5 million order from ClearPoint Neuro

Clinical Laserthermia Systems receives SEK 5.5 million order from ClearPoint Neuro

Report this content

Lund, Sverige – Clinical Laserthermia Systems AB (publ) (CLS) today announced it has received an order for ClearPoint Prism Neuro Laser Therapy System products from ClearPoint Neuro, Inc (Nasdaq:CLPT). The deal has a total value of SEK 5.5 million.


On September 23 2022, CLS received US FDA 510(k) clearance for its laser ablation system for use with MRI guidance in neurosurgery. Immediately followed by CLS’s global distributor initiating commercialization under the new brand name ClearPoint Prism Neuro Laser Therapy System.


CLS has now received the first order for ClearPoint Prism™ Neuro Laser Therapy System products worth SEK 5.5 million. The order is a consequence of ClearPoint Neuro’s initiated rollout in the US.


“I am very pleased to have received the first commercial order in our most important market – the US – and in one of our most important therapeutic areas, neurosurgery. With the ability to streamline minimally invasive neuro procedures, offered by this integrated one-stop-shop solution, we expect the ClearPoint Prism™ Neuro Laser Therapy System to become one of the leading products in the field of MRI-guided laser ablation in the brain", says Dan J. Mogren, CLS CEO


The ClearPoint Prism™ Neuro Laser Therapy System enables integration with the ClearPoint neuro navigation platform and MRI scanners from leading manufacturers. The system is now being rolled out in the United States for use within neurosurgery.



Contact information:

Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)705 – 90 11 40 E-mail: dan.mogren@clinicallaser.com




About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG® Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company’s interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se



For more information about CLS, please visit the Company's website: www.clinicallaser.se




About ClearPoint Neuro

ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active sites in the United States, Canada, and Europe. ClearPoint Neuro is partnered with more than 45 pharmaceutical and biotech companies, academic institutions, and contract research organizations providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 5,000 cases have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.


This disclosure contains information that CLS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-10-2022 12:00 CET.


Documents & Links